Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service antireflux & hiatal hernia surgery cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (180 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 141 | 40% |
| 2020 | 1 | 120 | 43% |
| 2021 | 2 | 129 | 46% |
| 2022 | 0 | 76 | 50% |
| 2023 | 2 | 102 | 53% |
| 2024 | 1 | 129 | 54% |
| 2025 from claims | – | 126 102–148 | 54% |
| 2026 forecast | – | 127 99–159 | 55% |
| 2027 forecast | – | 128 95–169 | 55% |
| 2028 forecast | – | 129 91–178 | 56% |
| 2029 forecast | – | 130 89–187 | 56% |
| 2030 forecast | – | 131 86–195 | 56% |
Laparoscopic fundoplication and paraesophageal hernia repair. Professional codes (what the surgeon bills): CPT 43280, 43281, 43282; the hospital bills MS-DRG 326, 327, 328.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 23% inpatient hospital, 77% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 37 | 2,040+1.2%/yr | +1.2%/yr | 0.6 | 0% | 2,990 in 2030+6.6%/yr |
| Arizona | 15 | 620−1%/yr | −1%/yr | 0.8 | 0% | 820 in 2030+4.8%/yr |
| Washington | 11 | 544+0.4%/yr | +0.4%/yr | 0.7 | 0% | 760 in 2030+5.7%/yr |
| Colorado | 10 | 529+3.9%/yr | +3.9%/yr | 1.1 | 0% | 750 in 2030+6.1%/yr |
| Oregon | 3 | 328−6.4%/yr | −6.4%/yr | 0.8 | 0% | 390 in 2030+2.9%/yr |
| Utah | 3 | 239−2.8%/yr | −2.8%/yr | 1.1 | 0% | 170 in 2030−5.1%/yr |
| Idaho | 4 | 195−6.6%/yr | −6.6%/yr | 1.0 | 0% | 260 in 2030+4.7%/yr |
| Nevada | 2 | 177−7.6%/yr | −7.6%/yr | 0.6 | 0% | 200 in 2030+2.1%/yr |
| Montana | 2 | 173+3.7%/yr | +3.7%/yr | 0.9 | 0% | 180 in 2030+0.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 11 | 986−2.8%/yr | −2.8%/yr | 4.50.8× | 1% | 970 in 2030−0.2%/yr |
| Cholecystectomy & appendectomy | 9 | 736−6.4%/yr | −6.4%/yr | 3.30.9× | 0% | 870 in 2030+2.8%/yr |
| Colorectal resection | 0 | 182−11%/yr | −11%/yr | 0.80.6× | 0% | 170 in 2030−1.5%/yr |
Antireflux & hiatal hernia surgery in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
No company payments named for these products in New Mexico in 2025.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.